Effective pharmaceutical regulation needs alignment with doctors

Drug Discovery Today

Volumn 17, Issue 3-4, 2012, Pages 100-103

  Ebbers, Hans C ^a   Pieters, Toine ^a,b   Leufkens, Hubert G ^a,c   Schellekens, Huub ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; RECOMBINANT ERYTHROPOIETIN; SB 309; UNCLASSIFIED DRUG;

DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PHARMACEUTICAL ENGINEERING; PHYSICIAN; PRACTICE GUIDELINE; PURE RED CELL ANEMIA; RECURRENT DISEASE; REVIEW;

EID: 84856478108     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.09.018     Document Type: Short Survey

References (22)

1. European Medicines Agency (2010) Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2010/04/WC500089474.pdf [Accessed April 11, 2011]
2. C.J. Kelly, and F.A. Mir Economics of biological therapies BMJ 339 2009 b3276
3. P.J. Declerck Biosimilars: controversies as illustrated by rhGH Curr. Med. Res. Opin. 26 2010 1219 1229
4. J.L. Bouchet Position statement regarding usage of biosimilars: position paper of the Societe de nephrologie, Societe francophone de dialyse, and Societe de nephrologie pediatrique Nephrol. Ther. 2 2006 432 435
5. D. Niederwieser, and S. Schmitz Biosimilar agents in oncology/ haematology: from approval to practice Eur. J. Haematol. 86 2011 277 288
6. P.A. Meredith Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms Curr. Med. Res. Opin. 25 2009 2179 2189
7. European Commission (2003) Directive 2003/63/EC. Off. J. L 159, 27/6/2003, 46-94. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX: 32003L0063:en:NOT [Accessed February 14, 2011]
8. N. Casadevall Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N. Engl. J. Med. 346 2002 469 475 (Pubitemid 34441737)
9. H. Schellekens, and W. Jiskoot Erythropoietin-associated PRCA: still an unsolved mystery J. Immunotoxicol. 3 2006 123 130 (Pubitemid 44266961)
10. European Medicines Agency (2005) Submission of comments. Guideline on Similar Biological Medicinal Products containing biotechnology derived products as active substance: non-clinical and clinical issues Annex: recombinant erythropoietin containing products (EMEA/CHMP/945626/2005) http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003923. pdf [Accessed May 10, 2011]
11. A. Covic Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA council Nephrol. Dial. Transplant 23 2008 3731 3737
12. W. Jelkmann Biosimilar epoetins and other 'follow-on' biologics: update on the European experiences Am. J. Hematol. 85 2010 771 780
13. M. Liefner Biosimilars: price dynamics in Europe N. Mattison, Biosimilars: How Much Entry and Price Competition Will Result? 2010 Office of Health Economics 51 60
14. K. Boven The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes Kidney Int. 67 2005 2346 2353 (Pubitemid 41623396)
15. B. Sharma Reactions to Eprex's adverse reactions Nat. Biotechnol. 24 2006 1199 1200
16. P. Minghetti The regulatory framework of biosimilars in the European Union Drug Discov. Today 2011 (Epub ahead of print)
17. European Medicines Agency (2011) Overview of comments received on the Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (EMEA/CHMP/BMWP/ 301636/2008) http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003923.pdf [Accessed May 10, 2011]
18. A. Breckenridge Evolution of regulatory frameworks Nat. Rev. Drug Discov. 10 2011 3 4
19. H. Prosser, and T. Walley A qualitative study of GPs' and PCO stakeholders' views on the importance and influence of cost on prescribing Soc. Sci. Med. 60 2005 1335 1346 (Pubitemid 40038762)
20. European Medicines Agency. (2011) Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins (EMEA/CHMP/BMWP/118264/2007)
21. Food and Drug Administration (2010) Public hearing on approval pathway for biosimilar and interchangeable biological products, 11/2/2010 Transcript. Doc ID; FDA-2010-N-0477-0011, http://www.regulations.gov/#!documentDetail;D=FDA- 2010-N-0477-0011;oldLink=false
22. European Medicines Agency (2011) Work programme 2011 (EMA/MB/482208/2010) http://www.ema.europa.eu/docs/en-GB/document-library/Work-programme/2011/02/ WC500102044.pdf [Accessed May 11, 2011]